TickerFacts.

Compare

Mirum Pharmaceuticals, Inc. vs BridgeBio Pharma, Inc. vs HUTCHMED (China) Ltd vs Travere Therapeutics, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearMirum Pharmaceuticals, Inc.
MIRM		BridgeBio Pharma, Inc.
BBIO		HUTCHMED (China) Ltd
HCM		Travere Therapeutics, Inc.
TVTX
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$521.31M$502.08M$548.51M$490.73M
Revenue growth (YoY)+54.7%+126.3%-13.0%+110.5%
Gross marginn/an/a38.7% (computed)n/a
Operating margin-4.2%-104.2%-7.1%-12.8%
Net margin-4.5%-146.0%83.3%-5.2%
Net income-$23.36M-$732.94M$456.91M-$25.55M
EPS (Diluted)-$0.47-$3.78$0.52-$0.29
Operating cash flow$55.83M-$445.91M-$64.66M$37.78M
Free cash flow$54.87M-$447.01M-$78.81Mn/a
Cash & equivalents$296.68M$570.12M$71.33M$93.03M
Total assets$842.81M$936.02M$1.75B$605.19M
Total liabilities$528.12M$3.01B$501.83M$490.36M
Shareholders' equity$314.69M-$2.09B$1.25B$114.83M
Return on year-end equity-7.4%n/a36.5%-22.2%
Shares outstanding51.90M194.77Mn/a90.92M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearMirum Pharmaceuticals, Inc.BridgeBio Pharma, Inc.HUTCHMED (China) LtdTravere Therapeutics, Inc.
Latest$521.31M
Ended 2025-12-31		$502.08M
Ended 2025-12-31		$548.51M
Ended 2025-12-31		$490.73M
Ended 2025-12-31
1 year earlier$336.89M
Ended 2024-12-31		$221.90M
Ended 2024-12-31		$630.20M
Ended 2024-12-31		$233.18M
Ended 2024-12-31
2 years earlier$186.37M
Ended 2023-12-31		$9.30M
Ended 2023-12-31		$838.00M
Ended 2023-12-31		$145.24M
Ended 2023-12-31
3 years earlier$77.06M
Ended 2022-12-31		$77.65M
Ended 2022-12-31		$426.41M
Ended 2022-12-31		$109.46M
Ended 2022-12-31
4 years earlier$19.14M
Ended 2021-12-31		$69.72M
Ended 2021-12-31		$356.13M
Ended 2021-12-31		$131.84M
Ended 2021-12-31